Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Curadev Pharma Private Limited.

    Client Virtual Booth

    CURADEV PHARMA PRIVATE LIMITED

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Curadev Pharma Private Limited
    india-flag Flag
    Country
    Country
    India
    Address
    Address
    B 87, Sector 83, Noida, UP 201305
    Telephone
    Telephone
    +91-120-408 1818/19
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.curadev.in/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/curadev-pharma-private-limited
    Twitter
    Twitter
    https://twitter.com/hashtag/curadev?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI...

    Details:

    CRD3874-SI is a small molecule drug designed to target the STimulator of INterferon Genes, to activate immune cells to identify and eradicate tumors. It is being evaluated for the treatment of sarcoma & merkel cell carcinoma.


    Lead Product(s): CRD3874-SI

    Therapeutic Area: Oncology Product Name: CRD3874-SI

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications

    Details:

    The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Bayer AG

    Deal Size: $270.4 million Upfront Cash: Undisclosed

    Deal Type: Collaboration March 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search